Skip Navigation


QJM Advance Access originally published online on January 15, 2009
QJM 2009 102(4):293-296; doi:10.1093/qjmed/hcp001
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
102/4/293    most recent
hcp001v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Younis, N.
Right arrow Articles by Hassanein, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Younis, N.
Right arrow Articles by Hassanein, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Cardiovascular disease and intensive glucose lowering in type 2 diabetes

N. Younis1, H. Soran2 and M. Hassanein3

From the 1 Department of Endocrinology, University Hospital of South Manchester NHS Trust, Manchester, 2Department of Medicine, Manchester Royal Infirmary and 3Diabetes Department, Glan Clwyd Hospital, Rhyl, North Wales, UK

Address correspondence to Dr N. Younis, University Hospital of South Manchester, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester, M23-9LT, Canada. email: naveedy@tinyonline.co.uk

The first 150 words of the full text of this article appear below.

The leading cause of death in type 2 diabetes is cardiovascular disease accounting for an increased risk of up to two to four times compared with those without diabetes. Prospective studies have shown positive associations of blood glucose and glycated haemoglobin levels with higher risks of cardiovascular events. To date the benefits of intervention of long-term reduction in blood glucose levels on cardiovascular events is unclear. This article reviews the results of recent major clinical trials that address whether near normal glucose levels in patients with type 2 diabetes can reduce the risk of cardiovascular events.

The leading cause of death in type 2 diabetes is cardiovascular disease accounting for an increased risk of up to two to four times for ischaemic heart disease and stroke compared with those without diabetes.1,2 Prospective epidemiological studies have shown associations of increasing blood glucose and glycosylated haemoglobin levels with higher risks of cardiovascular . . . [Full Text of this Article]


   Action to Control Cardiovascular Risk in Diabetes
 

   The Action in Diabetes and Vascular Disease Study
 

   Veterans Affair Diabetes Trial
 

   United Kingdom Prospective Diabetes Study post-trial study
 

   Commentary
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?